news
Neuroprotection in NAION: QPI-1007 Fails Primary Endpoint but Shows Promise in Severe Vision Loss
This Phase 2/3 trial of QPI-1007 for NAION found that while the primary endpoint was not met for the general population, the siRNA therapy significantly preserved vision in patients with more severe baseline visual impairment.
